183 related articles for article (PubMed ID: 31258764)
1. Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma.
Zhang W; Song Z; Xiao J; Liu X; Luo Y; Yang Z; Luo R; Li A
J Cancer; 2019; 10(11):2578-2587. PubMed ID: 31258764
[TBL] [Abstract][Full Text] [Related]
2. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE.
Zhang J; Li H; Gao D; Zhang B; Zheng M; Lun M; Wei M; Duan R; Guo M; Hua J; Liu Q; Bai J; Liu H; Zheng J; Yao H
Cancer Biol Ther; 2018 Jun; 19(6):475-483. PubMed ID: 29400599
[TBL] [Abstract][Full Text] [Related]
3. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
[TBL] [Abstract][Full Text] [Related]
4. Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice.
Jung NC; Lee JH; Choi HJ; Hwang SU; Song JY; Seo HG; Choi J; Jung SY; Han SG; Lim DS
Immunol Invest; 2016 Aug; 45(6):553-65. PubMed ID: 27410037
[TBL] [Abstract][Full Text] [Related]
5. Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system.
Yang T; Zhang W; Wang L; Xiao C; Wang L; Gong Y; Huang D; Guo B; Li Q; Xiang Y; Nan Y
BMC Cancer; 2018 Oct; 18(1):984. PubMed ID: 30326865
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Chen CL; Pan QZ; Zhao JJ; Wang Y; Li YQ; Wang QJ; Pan K; Weng DS; Jiang SS; Tang Y; Zhang XF; Zhang HX; Zhou ZQ; Zeng YX; Xia JC
Oncoimmunology; 2016 Jul; 5(7):e1176653. PubMed ID: 27622026
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer.
Chen J; Chen Y; Feng F; Chen C; Zeng H; Wen S; Xu X; He J; Li J
J Thorac Dis; 2018 Dec; 10(12):6711-6721. PubMed ID: 30746216
[TBL] [Abstract][Full Text] [Related]
8. Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.
Chen CL; Pan QZ; Weng DS; Xie CM; Zhao JJ; Chen MS; Peng RQ; Li DD; Wang Y; Tang Y; Wang QJ; Zhang ZL; Zhang XF; Jiang LJ; Zhou ZQ; Zhu Q; He J; Liu Y; Zhou FJ; Xia JC
Oncoimmunology; 2018; 7(4):e1417721. PubMed ID: 29632736
[TBL] [Abstract][Full Text] [Related]
9. PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines.
Li Y; Sharma A; Bloemendal MWJR; Schmidt-Wolf R; Kornek M; Schmidt-Wolf IGH
Oncol Lett; 2021 Aug; 22(2):613. PubMed ID: 34257721
[TBL] [Abstract][Full Text] [Related]
10. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
11. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.
Wei F; Rong XX; Xie RY; Jia LT; Wang HY; Qin YJ; Chen L; Shen HF; Lin XL; Yang J; Yang S; Hao WC; Chen Y; Xiao SJ; Zhou HR; Lin TY; Chen YS; Sun Y; Yao KT; Xiao D
Oncotarget; 2015 Oct; 6(33):35023-39. PubMed ID: 26418951
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.
González-Carmona MA; Märten A; Hoffmann P; Schneider C; Sievers E; Schmidt-Wolf IG; Sauerbruch T; Caselmann WH
Liver Int; 2006 Apr; 26(3):369-79. PubMed ID: 16584401
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model.
Teng CF; Wang T; Wu TH; Lin JH; Shih FY; Shyu WC; Jeng LB
Ther Adv Med Oncol; 2020; 12():1758835920922034. PubMed ID: 32565925
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis.
Liu Y; Mu Y; Zhang A; Ren S; Wang W; Xie J; Zhang Y; Zhou C
Onco Targets Ther; 2017; 10():1897-1908. PubMed ID: 28408841
[TBL] [Abstract][Full Text] [Related]
16. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK.
Wang QJ; Wang H; Pan K; Li YQ; Huang LX; Chen SP; He J; Ke ML; Zhao JJ; Li JJ; Sun JC; Liang XT; Ma HQ; Chen YB; Xia JC
Chin J Cancer; 2010 Jul; 29(7):641-8. PubMed ID: 20591215
[TBL] [Abstract][Full Text] [Related]
17. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.
Li Y; Sharma A; Wu X; Weiher H; Skowasch D; Essler M; Schmidt-Wolf IGH
Front Oncol; 2022; 12():713476. PubMed ID: 35646685
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.
Lin T; Song C; Chuo DY; Zhang H; Zhao J
Tumour Biol; 2016 Apr; 37(4):4367-72. PubMed ID: 26499782
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Receptor 1 (PD1) Knockout and Human Telomerase Reverse Transcriptase (hTERT) Transduction Can Enhance Persistence and Antitumor Efficacy of Cytokine-Induced Killer Cells Against Hepatocellular Carcinoma.
Huang K; Sun B; Luo N; Guo H; Hu J; Peng J
Med Sci Monit; 2018 Jul; 24():4573-4582. PubMed ID: 29967316
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients.
Chen F; Yang M; Song Q; Wu J; Wang X; Zhou X; Yuan Y; Song Y; Jiang N; Zhao Y; Zhou L; Ren J
Mol Clin Oncol; 2017 Nov; 7(5):903-910. PubMed ID: 29181186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
